Guggenheim Reiterates Neutral Rating on Amgen (AMGN)

October 26, 2026 6:49 AM EDT Send to a Friend
Guggenheim analyst Vamil Divan reiterated a Neutral rating and $378.00 price target on Amgen (NASDAQ: AMGN).The analyst commented: "In this ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login